

The exercise period for warrants series TO 3 in Amniotics begins today

The exercise period for warrants series TO 3 (the “Warrants”) that were issued in conjunction with Amniotics AB’s (“Amniotics” or the “Company”) rights issue of units which was announced on August 31, 2023 (the “Rights Issue”) begins today, February 26, 2024.

Terms for the Warrants in brief:

The exercise price is SEK 0.01 per share.

The exercise period runs from February 26 – March 8, 2024.

Upon full exercise of all Warrants, a maximum of 2,502,044,100 shares may be added.

Upon full exercise of all Warrants, the Company will receive approximately MSEK 25 before issue costs.

Upon full exercise of all Warrants, the number of shares in Amniotics will increase with 2,502,044,100 shares to 5,212,591,875 shares and the share capital will increase with SEK 6,004,905.84 to SEK 12,510,220.50.

The announcement of the outcome is planned to: March 9, 2024.

In total, Amniotics issued 2,502,044,100 units in the Rights Issue, each consisting of one (1) share and one (1) Warrant. The exercise period of the Warrants will run from today, February 26, 2024, until March 8, 2024. One (1) Warrant entitles the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.01 per share.

In the event of full exercise of all Warrants, the Company will receive approximately MSEK 25 before issue costs. In order for the Warrants not to expire and lose their value, they must be actively sold by March 6, 2024, at the latest or alternatively exercised for subscription of shares by March 8, 2024.

In the event of full exercise of all Warrants for subscription of shares, the Company will raise approximately MSEK 25 before issue costs. Complete terms and conditions for the Warrants are available at Amniotics’ website www.amniotics.com.

Note that Warrants that have not been actively sold by March 6, 2024, at the latest or alternatively exercised for subscription of shares by March 8, 2024, will expire and lose their value.

Exercise of Warrants

Trustee-registered Warrants

If the warrant holder holds Warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the Warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercising of the Warrants.

Directly registered Warrants (securities account)

Registration is done through a registration form available on the websites of Nordic Issuing AB www.nordic-issuing.se, Redeye AB www.redeye.se and Amniotics www.amniotics.com. Payment is made in accordance with the instructions on the registration form. Both the registration form and payment must be submitted to Nordic Issuing AB by March 8, 2024, at the latest.

Advisors

Redeye AB acts as financial advisor and Setterwalls Advokatbyrå AB acts as legal advisor to Amniotics in connection with the Rights Issue. Nordic Issuing AB acts as issuer agent in connection with the Rights Issue.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and Warrants in Amniotics has only taken place through the prospectus that Amniotics published on October 10, 2023.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Attachments

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 08 40 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Attachments

[The exercise period for warrants series TO 3 in Amniotics begins today](#)